LICENSING OF PHARMACEUTICAL
We are looking for exclusive regional or local licensing and distribution rights for ethical pharmaceutical (Rx and OTC) and consumer health products in areas with a high, yet unmet need. We are interested in ready-to-market, finished products or innovative drug candidates in late-stage clinical development (clinical phase 3 for standard pharmaceuticals; phase 2 proof-of-concept for orphan drugs).
Our key therapeutic areas of interest are gastroenterology, neurology (CNS), oncology including haematology, immunology and in particular inflammatory, autoimmune and respiratory disorders, and infectious diseases. Ewopharma also covers treatments for internal medicine, paediatrics, gynaecology, hepatology, nephrology, dermatology and radiology.
If your licensing opportunity lies outside of our core focus areas, we are still interested in hearing about it. We have an opportunistic approach and are open to evaluating any asset that could be promising for our current or future product portfolio.
Access to orphan drugs is an on-going challenge in Central Eastern Europe, where in some countries, many orphan drugs approved by the European Medicines Agency (EMA) are not even registered let alone reimbursed. Both the small market size and limited public healthcare resources contribute to this situation, leaving many rare-disease patients in a particularly vulnerable situation. Increasing access to such drugs and enabling rare disease patients to obtain the therapies they need, is one of Ewopharma’s key objectives.
Ewopharma is ideally placed to take on products that may just be under the radar of “Big Pharma” but still meet market demand, such as those providing an alternative or more cost-effective option to an existing product. These so-called niche generics are distributed in either hospitals or retail settings (pharmacies).
Ewopharma employs highly qualified Medical Sales Representatives. Most have university degrees in medicine or pharmacy. Every representative is responsible for a specific region and product group within their country. Hospital specialities include any products for a faculty located within a hospital, for example, internal medicine, nephrology, or oncology.
Ewopharma also commercializes products in larger areas, such as “cough and cold” or respiratory infectious diseases, where patients are numerous, but existing treatment options do not adequately meet their needs. For years, we have been successfully marketing our own brand Isorpinosine®, a drug that combines both antiviral and immunomodulatory properties. We are particularly interested in non-prescription cough and cold preparations supported by clinical evidence and products that contain innovative active components.
Whether you have strong heartburn, stomach ache, diarrhoea, gas, bloating, constipation, nausea, or vomiting, gastrointestinal woes can wreak havoc on our lives. Treatment often includes a combination of medication and lifestyle changes. Ewopharma is looking for innovative nutraceuticals with therapeutic effects to improve gastrointestinal health, prevent chronic diseases or support the function of the body as a whole.
Revalid®, an Ewopharma own brand, was developed in Switzerland in 1992 to provide holistic hair care and hair loss treatment. The Revalid® Hair Care system consists of medicinal capsules, which strengthen the hair from the inside, and a line of cosmetic hair care products for external use. The product range is continually evolving and expanding. We seek in-licensing opportunities for evidence-based anti-hair-loss technologies and innovative lifestyle cosmeceuticals to be marketed under the Revalid® brand.